Skip to content

Project AABUSS

Project research and development for adjunct automated breast ultrasonography screening system (AABUSS)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042240132
Enrollment
3000
Registered
2024-11-25
Start date
2025-05-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

In addition to mammography (MG) and breast tomosynthesis (BT) as breast cancer screening methods, the implementation of an Automated Breast Ultrasound System (ABUS) is proposed.

Sponsors

Uematsu Takayoshi
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1)Women who plan to undergo breast cancer screening by their own decision using MG/BT and ABUS. (2)Informed consent for participation in this study has been obtained through an electronic document, reflecting the voluntary agreement of the research subject themselves (3)Women who are between the ages of 35 and under 75 at the time of consent acquisition.

Exclusion criteria

Exclusion criteria: (1)Women who are pregnant or may become pregnant. (2)A woman with a history of breast cancer. (3)A woman who has undergone breast augmentation surgery (4)Individuals deemed unsuitable for participation in this study by the principal investigator or co-investigator.

Design outcomes

Primary

MeasureTime frame
Assess the presence of specificity reduction due to the addition of ABUS when comparing the specificity of ABUS combined with MG/BT screening to MG/BT screening alone.

Secondary

MeasureTime frame
- Compare the sensitivity of MG/BT screening with and without the addition of ABUS to evaluate the supplementary effect of ABUS. - Assess the additive effect of ABUS when used in conjunction with MG/BT screening by comparing the breast cancer detection rates of MG/BT screening alone and in combination with ABUS. - Comparison of recall rates and positive predictive values between MG/BT alone and the combined use of MG/BT and ABUS. - Evaluate the non-inferiority of cancer detection rates using ABUS alone compared to MG/BT alone. - For ABUS assessments, employ double reading and evaluate the concordance rate between the first and second readers' interpretations.

Contacts

Public ContactTakayoshi Uematsu

Shizuoka Cancer Center

t.uematsu@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026